2019
DOI: 10.1002/aic.16688
|View full text |Cite
|
Sign up to set email alerts
|

Comprehensive mutagenesis on yeast cytosine deaminase yields improvements in 5‐fluorocytosine toxicity in HT1080 cells

Abstract: Improved prodrug‐activating enzymes have the potential to increase the therapeutic efficacy of gene‐directed enzyme prodrug therapy (GDEPT). Yeast cytosine deaminase (yCD) is commonly used to convert the prodrug 5‐fluorocytosine (5‐FC) to the chemotherapeutic 5‐fluorouracil for GDEPT. Mutagenesis studies on yCD aimed at improving its application in GDEPT have been limited to subsets of residues or have sought to improve a single property of the enzyme. We performed comprehensive site‐saturation mutagenesis (CS… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
4
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 26 publications
0
4
0
1
Order By: Relevance
“…The lack of cytosine deaminase activity in humans has made the enzyme a promising candidate for pro-drug gene therapy, where it is targeted to cancer cells to induce tumor specific toxicity 17,18 . This has led to extensive engineering of Fcy1p to optimize its properties as a pro-drug gene therapeutic agent [19][20][21] . Because of this wealth of knowledge, .…”
Section: Introductionmentioning
confidence: 99%
“…The lack of cytosine deaminase activity in humans has made the enzyme a promising candidate for pro-drug gene therapy, where it is targeted to cancer cells to induce tumor specific toxicity 17,18 . This has led to extensive engineering of Fcy1p to optimize its properties as a pro-drug gene therapeutic agent [19][20][21] . Because of this wealth of knowledge, .…”
Section: Introductionmentioning
confidence: 99%
“…The lack of cytosine deaminase activity in humans has made the enzyme a promising candidate for pro-drug gene therapy, where it is targeted to cancer cells to induce tumor specific toxicity 17, 18 . This has led to extensive engineering of Fcy1p to optimize its properties as a pro-drug gene therapeutic agent 1921 . Because of this wealth of knowledge, Fcy1p is a powerful model to study the evolution of resistance and the potentially associated trade-offs.…”
Section: Introductionmentioning
confidence: 99%
“…The changes in the abundance of each mutant are then used to calculate the ratio of sequence counts before and after selection, which can be used to estimate the relative activities of mutant proteins. This approach has been applied to diverse proteins that function in cellular catalysis. However, it has not yet been applied to multiheme cytochromes that mediate EET.…”
mentioning
confidence: 99%